| Cat. No. |
Product Name |
Information |
| PC-27991 |
XY0206
FLT3 inhibitor
|
XY0206 is a potent and oral FMS-like tyrosine kinase 3 (FLT3) inhibitor with IC50 of 0.7 nM, 5.27 nM and 6.92 nM for FLT3-ITD, FLT3 and RET, suppresses downstream STAT5, AKT, and ERK signaling, resulting in apoptosis in FLT3-ITD AML cells. |
| PC-25801 |
LT-540-717
FLT3 inhibitor
|
LT-540-717 is a potent, selective and orally available FLT3 inhibitor with IC50 of 0.62 nM, inhibits FLT3 mutations FLT3 (ITD), FLT3 (D835V), FLT3 (ITD, D835V), FLT3 (ITD, F69L) with IC50 of 18.22, 1.54, 0.58 and 1.61 nM, respectively. |
| PC-24405 |
Clifutinib
FLT3-ITD inhibitor
|
Clifutinib (HEC73543) is potent, selective FLT3-ITD (internal tandem duplication mutations of FLT3) inhibitor with biochemical IC50 of 15.1 nM, exhibits significant antiproliferative activity against Ba/F3-FLT3-ITD cells with IC50 of 0.9 nM. |
| PC-24328 |
CHMFL-FLT3-122
FLT3 inhibitor
|
CHMFL-FLT3-122 (HYML-122, TR122) is a potent, selective and orally active FLT3 kinase with IC50 of 40 nM, shows >10-fold selectivity over BTK (IC50=421 nM) and c-KIT (IC50=559 nM) kinases, also selectively targets RIPK2 kinase with IC50 of 14 nM. |
| PC-24149 |
Lomonitinib
FLT3/IRAK4 inhibitor
|
Lomonitinib (ZE46-0134) is a highly potent and selective pan-FLT3/IRAK4 inhibitor, targets clinically relevant FLT3 mutations (ITD, TKD) including the gatekeeper mutation, as well as IRAK4, a putative escape pathway for FLT3-driven acute myeloid leukemia (AML). |
| PC-24145 |
PHI-101
FLT3 inhibitor
|
Lasmotinib (PHI-101) is a potent, selectivean orally bioavailable next-generation FLT3 inhibitor, potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. |
| PC-23628 |
SILA-123
FLT3 inhibitor
|
SILA-123 (SILA123) is a potent, selective type II FLT3 inhibitor with IC50 of 2.1 nM and 1.0 nM for FLT3-WT and FLT3-ITD respectively. |
| PC-23460 |
SKLB1028
EGFR/FLT3/Abl inhibitor
|
SKLB1028 (Ruserontinib) is a potent, oral multikinase inhibitor of EGFR, FLT3 and Abl with IC50 of 55 nM (FLT3), potently inhibits the wild-type and L858R-mutant EGFR with IC50 values of 31 nM and 4 nM, respectively. |
| PC-22539 |
HSN748
FLT3 inhibitor
|
HSN748 is potent, selective, type II inhibitor of FLT3 (Kd=0.15 nM) and FLT3 mutants (FLT3 D835Y, KD=1.4 nM), shows potently effective against drug-resistant secondary mutations of FLT3. |
| PC-21565 |
TSN084
Multikinase inhibitor
|
TSN084 (TSN 084) is a unique small molecule multi-kinase inhibitor of drug-resistant mutations of c-Met, Trks, and Flt3, also inhibits other oncotargets including Axl, DDRs, and CDK8/19. |
| PC-21047 |
YHJ1039
FLT3 inhibitor
|
YHJ1039 is a broad-spectrum kinase inhibitor, possesses excellent potencies against FLT3 mutants (FLT3 D835Y, IC50=0.41 nM) as well as FAK (IC50=7 nM). |
| PC-20211 |
PCW-A1001
FLT3 D835Y inhibitor
|
PCW-A1001 is a potent, selective inhibitor of FLT-3 (D835Y) mutant with IC50 of 764 nM, weakly inhibits WT FLT-3 with IC50 of 2.54 uM. |
